Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial
Authors:
- Andrew GreyAGAndrew Grey
- Mark J. BollandMBMark J. Bolland
- Anne HorneAHAnne Horne
- Diana WattieDWDiana Wattie
- Meaghan HouseMHMeaghan House
- Greg GambleGGGreg Gamble
- Ian R. ReidIRIan R. Reid
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Prolonged antiresorptive activity of zoledronate: A randomized, controlled trialJournal of Bone and Mineral Research, 2010
- Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone MassObstetrics & Gynecology, 2009
- The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2009
- Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 MonthsJournal of Bone and Mineral Research, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- A systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporosis International, 2007
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Compliance with osteoporosis therapy is the weakest linkThe Lancet, 2006
- OsteoporosisThe Lancet, 2006